Galsulfase (Naglazyme®)

Covered only for the FDA‑approved indication mucopolysaccharidosis type VI (MPS VI); other indications are excluded. Approval (up to 12 months) requires documented deficient arylsulfatase B activity or pathogenic ARSB gene mutation, prescription by or consultation with an appropriate specialist (geneticist, endocrinologist, metabolic/lysosomal disorder specialist), documentation of patient weight for the recommended 1 mg/kg IV weekly dosing, and sufficient medical records for reauthorization.

"Naglazyme (galsulfase) is indicated for the treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy Syndrome)."

Sign up to see full coverage criteria, indications, and limitations.